Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib

Leuk Res. 2010 Aug;34(8):e215-6. doi: 10.1016/j.leukres.2010.02.037. Epub 2010 Mar 23.

Authors

M Defina, A Gozzetti, M Rondoni, L Aprile, M Ippoliti, I Chitarrelli, F Lauria, M Bocchia

PMID: 20334915
DOI: 10.1016/j.leukres.2010.02.037

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Male
Middle Aged
Neoplasm Recurrence, Local / diagnosis*
Piperazines / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / therapeutic use*
Time Factors
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases